AKBLF
Price
$28.20
Change
+$0.55 (+1.99%)
Updated
Jul 2 closing price
Capitalization
6.51B
CVALF
Price
$1.90
Change
+$0.09 (+4.97%)
Updated
Jul 3 closing price
Capitalization
52.24M
Interact to see
Advertisement

AKBLF vs CVALF

Header iconAKBLF vs CVALF Comparison
Open Charts AKBLF vs CVALFBanner chart's image
Alk Abello AS
Price$28.20
Change+$0.55 (+1.99%)
Volume$65
Capitalization6.51B
Covalon Technologies
Price$1.90
Change+$0.09 (+4.97%)
Volume$3.1K
Capitalization52.24M
AKBLF vs CVALF Comparison Chart in %
Loading...
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CVALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBLF vs. CVALF commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBLF is a Buy and CVALF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (AKBLF: $28.20 vs. CVALF: $1.90)
Brand notoriety: AKBLF and CVALF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBLF: 934% vs. CVALF: 61%
Market capitalization -- AKBLF: $6.51B vs. CVALF: $52.24M
AKBLF [@Biotechnology] is valued at $6.51B. CVALF’s [@Biotechnology] market capitalization is $52.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBLF’s FA Score shows that 0 FA rating(s) are green whileCVALF’s FA Score has 0 green FA rating(s).

  • AKBLF’s FA Score: 0 green, 5 red.
  • CVALF’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBLF is a better buy in the long-term than CVALF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBLF’s TA Score shows that 3 TA indicator(s) are bullish while CVALF’s TA Score has 3 bullish TA indicator(s).

  • AKBLF’s TA Score: 3 bullish, 2 bearish.
  • CVALF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AKBLF is a better buy in the short-term than CVALF.

Price Growth

AKBLF (@Biotechnology) experienced а +1.99% price change this week, while CVALF (@Biotechnology) price change was +4.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBLF($6.51B) has a higher market cap than CVALF($52.2M). AKBLF has higher P/E ratio than CVALF: AKBLF (42.64) vs CVALF (17.29). AKBLF YTD gains are higher at: 26.174 vs. CVALF (-15.179). AKBLF has higher annual earnings (EBITDA): 1.55B vs. CVALF (4.73M). AKBLF has more cash in the bank: 517M vs. CVALF (18M). CVALF has less debt than AKBLF: CVALF (609K) vs AKBLF (800M). AKBLF has higher revenues than CVALF: AKBLF (5.71B) vs CVALF (33.8M).
AKBLFCVALFAKBLF / CVALF
Capitalization6.51B52.2M12,475%
EBITDA1.55B4.73M32,840%
Gain YTD26.174-15.179-172%
P/E Ratio42.6417.29247%
Revenue5.71B33.8M16,888%
Total Cash517M18M2,872%
Total Debt800M609K131,363%
FUNDAMENTALS RATINGS
AKBLF vs CVALF: Fundamental Ratings
AKBLF
CVALF
OUTLOOK RATING
1..100
3932
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
4568
SMR RATING
1..100
4955
PRICE GROWTH RATING
1..100
4160
P/E GROWTH RATING
1..100
8493
SEASONALITY SCORE
1..100
4550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CVALF's Valuation (63) in the null industry is in the same range as AKBLF (82). This means that CVALF’s stock grew similarly to AKBLF’s over the last 12 months.

AKBLF's Profit vs Risk Rating (45) in the null industry is in the same range as CVALF (68). This means that AKBLF’s stock grew similarly to CVALF’s over the last 12 months.

AKBLF's SMR Rating (49) in the null industry is in the same range as CVALF (55). This means that AKBLF’s stock grew similarly to CVALF’s over the last 12 months.

AKBLF's Price Growth Rating (41) in the null industry is in the same range as CVALF (60). This means that AKBLF’s stock grew similarly to CVALF’s over the last 12 months.

AKBLF's P/E Growth Rating (84) in the null industry is in the same range as CVALF (93). This means that AKBLF’s stock grew similarly to CVALF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBLFCVALF
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
24%
Bearish Trend 2 days ago
72%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
61%
MACD
ODDS (%)
Bearish Trend 2 days ago
20%
Bullish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
34%
Bullish Trend 2 days ago
54%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
34%
Bullish Trend 2 days ago
53%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
37%
Bearish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CVALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
USPX54.920.39
+0.72%
Franklin US Equity Index ETF
FFND28.030.17
+0.61%
One Global ETF
RSSB26.290.09
+0.32%
Return Stacked Global Stocks & Bonds ETF
ZDEK24.620.07
+0.29%
Innovator Equity Defined Prt ETF -1YrDec
JUNZ30.880.08
+0.25%
TrueShares Structured Outcome June ETF

AKBLF and

Correlation & Price change

A.I.dvisor tells us that AKBLF and MNPR have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKBLF and MNPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBLF
1D Price
Change %
AKBLF100%
N/A
MNPR - AKBLF
29%
Poorly correlated
+3.10%
MSCLF - AKBLF
27%
Poorly correlated
N/A
IOVA - AKBLF
26%
Poorly correlated
N/A
SMMT - AKBLF
25%
Poorly correlated
+8.53%
VBIZF - AKBLF
24%
Poorly correlated
N/A
More

CVALF and

Correlation & Price change

A.I.dvisor tells us that CVALF and SMMT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVALF and SMMT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVALF
1D Price
Change %
CVALF100%
+4.97%
SMMT - CVALF
27%
Poorly correlated
+8.53%
GNFT - CVALF
25%
Poorly correlated
-0.51%
AKBLF - CVALF
21%
Poorly correlated
N/A
TARA - CVALF
21%
Poorly correlated
+3.96%
MBIO - CVALF
20%
Poorly correlated
N/A
More